Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

37.5%

6 terminated/withdrawn out of 16 trials

Success Rate

45.5%

-41.1% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results6 terminated

Enrollment Performance

Analytics

Phase 2
7(46.7%)
Phase 1
6(40.0%)
Early Phase 1
1(6.7%)
Phase 3
1(6.7%)
15Total
Phase 2(7)
Phase 1(6)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT03899987Phase 2Active Not Recruiting

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Role: collaborator

NCT03734692Phase 1Active Not Recruiting

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Role: collaborator

NCT04379518Phase 1Terminated

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Role: collaborator

NCT00215813Unknown

Ampligen in Chronic Fatigue Syndrome

Role: lead

NCT05494697Phase 2Suspended

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Role: lead

NCT02432378Phase 1Terminated

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Role: collaborator

NCT05927142Phase 1Recruiting

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Role: collaborator

NCT05592418Phase 2Completed

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Role: lead

NCT01545141Phase 1Terminated

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Role: collaborator

NCT03599453Early Phase 1Completed

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Role: collaborator

NCT01591473Phase 1Terminated

Safety Study of FluMist With and Without Ampligen

Role: lead

NCT00215852Phase 2Terminated

A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects

Role: lead

NCT00215800Phase 3Completed

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Role: lead

NCT00035581Phase 2Terminated

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

Role: lead

NCT00035893Phase 2Completed

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

Role: lead

NCT00215826Phase 2Completed

Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

Role: lead

All 16 trials loaded